As of Jul 25, 2024, the HALO stock has a P/E ratio of 22.84. The calculation is based on the latest EPS of $2.45 and the stock price of $55.97 per share. An increase of 22% has been observed in the PE ratio compared to its average of 18.7 of the past four quarters.
The mean historical PE ratio of Halozyme Therapeutics over the last seven years is 33.66. The current 22.84 price-to-earnings ratio is 32% less than the historical average. Analyzing the last seven years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Mar 2022 quarter saw the lowest point at 12.95, with a price of $39.88 and an EPS of $3.08.
Maximum annual increase: 173.47% in 2022
Maximum annual decrease: -68.73% in 2021
| Year | PE ratio | Change |
|---|---|---|
| 2023 | 17.35 | -54.88% |
| 2022 | 38.45 | 173.47% |
| 2021 | 14.06 | -68.73% |
| 2020 | 44.96 | N/A |
| 2019 | N/A | N/A |
| 2018 | N/A | N/A |
| 2017 | 44.04 | N/A |
| 2016 | N/A | N/A |
| 2015 | N/A | N/A |
| 2014 | N/A | N/A |
The current PE ratio of HALO is above its 3-year average, but it is under its 5 and 10-year averages.
HALO's PE ratio is less than its peer stocks LLY and MNKD, but it is above JNJ's and BAX's.
| Stock name | PE ratio | Market cap |
|---|---|---|
| BAX Baxter International Inc | 6.79 | $18.1B |
| JNJ Johnson & Johnson | 10.55 | $386.7B |
| HALO Halozyme Therapeutics Inc | 22.95 | $7.16B |
| LLY ELI LILLY & Co | 117.98 | $764.72B |
| MNKD Mannkind Corp | 146 | $1.59B |
| PFE Pfizer Inc | N/A | $174.36B |
As of Jul 25, 2024, HALO stock has a price to earnings ratio of 22.84.
Over the last 3 years, the average PE ratio for HALO stock is 20.52.
Over the last 5 years, the average PE ratio for HALO stock is 31.93.
Over the last seven years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.
HALO's current price to earnings ratio is 32% below its 7-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Jul 25, 2024), Halozyme Therapeutics's share price is $55.97. The company's earnings per share for the trailing twelve months (TTM) ending Mar 2024 is $2.45. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 22.84. PE RATIO(22.84) = STOCK PRICE($55.97) / TTM EPS($2.45)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.